Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

536
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
536
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

236
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
236
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

4.2K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.2K
Disorders of Erythrocytes01:27

Disorders of Erythrocytes

1.3K
Disorders of erythrocytes, or red blood cells (RBCs), include a range of conditions affecting their number, shape, or function.
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
1.3K
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

337
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
337

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Carbidopa/levodopa products may induce vitamin B6 deficiency and seizures.

The American journal of nursing·2026
Same author

True generic of Flovent HFA inhaler now approved.

The American journal of nursing·2026
Same author

Second drug approved for achondroplasia.

The American journal of nursing·2026
Same author

Updates from the FDA on GLP-1 agonists.

The American journal of nursing·2026
Same author

More warnings about over-the-counter supplements containing hidden drugs.

The American journal of nursing·2026
Same author

Drug for iron deficiency is now approved for pediatric patients.

The American journal of nursing·2026

Related Experiment Video

Updated: Oct 2, 2025

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
05:23

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Published on: March 14, 2017

19.7K

New Treatment for Polycythemia Vera.

Diane S Aschenbrenner1

  • 1Diane S. Aschenbrenner is a former member of the faculty at Notre Dame of Maryland University and the Johns Hopkins University School of Nursing. She coordinates Drug Watch : diane.aschenbrenner@gmail.com .

The American Journal of Nursing
|February 24, 2022
PubMed
Summary

Ropeginterferon alfa-2b-njft (Besremi) is a new treatment for polycythemia vera, suitable for all patients. Healthcare providers must monitor for potential serious side effects.

More Related Videos

Ex Vivo Expansion of Hematopoietic Stem Cells from Human Umbilical Cord Blood-derived CD34+ Cells Using Valproic Acid
10:42

Ex Vivo Expansion of Hematopoietic Stem Cells from Human Umbilical Cord Blood-derived CD34+ Cells Using Valproic Acid

Published on: April 11, 2019

10.1K
Transduction-Transplantation Mouse Model of Myeloproliferative Neoplasm
08:12

Transduction-Transplantation Mouse Model of Myeloproliferative Neoplasm

Published on: December 22, 2016

12.1K

Related Experiment Videos

Last Updated: Oct 2, 2025

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
05:23

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Published on: March 14, 2017

19.7K
Ex Vivo Expansion of Hematopoietic Stem Cells from Human Umbilical Cord Blood-derived CD34+ Cells Using Valproic Acid
10:42

Ex Vivo Expansion of Hematopoietic Stem Cells from Human Umbilical Cord Blood-derived CD34+ Cells Using Valproic Acid

Published on: April 11, 2019

10.1K
Transduction-Transplantation Mouse Model of Myeloproliferative Neoplasm
08:12

Transduction-Transplantation Mouse Model of Myeloproliferative Neoplasm

Published on: December 22, 2016

12.1K

Area of Science:

  • Hematology
  • Pharmacology
  • Oncology

Background:

  • Polycythemia vera is a chronic myeloproliferative neoplasm.
  • Existing treatments have limitations or specific indications.
  • Interferon alfa has been used historically for myeloproliferative neoplasms.

Purpose of the Study:

  • To introduce ropeginterferon alfa-2b-njft (Besremi) as a novel therapeutic option.
  • To highlight its unique position as the first interferon approved for polycythemia vera, irrespective of treatment history.
  • To inform healthcare professionals about its administration and safety profile.

Main Methods:

  • Ropeginterferon alfa-2b-njft is administered subcutaneously.
  • The dosing frequency is every two weeks.
  • Clinical data supports its efficacy and safety in polycythemia vera patients.

Main Results:

  • Ropeginterferon alfa-2b-njft is the first approved interferon for polycythemia vera.
  • It is indicated for patients regardless of prior treatment.
  • The drug carries a boxed warning for potential serious adverse events.

Conclusions:

  • Ropeginterferon alfa-2b-njft offers a new treatment avenue for polycythemia vera.
  • Close patient monitoring for adverse effects is crucial.
  • Nurses play a key role in managing patients on this therapy.